Peter A. Fasching

researcher

Peter A. Fasching is …
instance of (P31):
humanQ5

External links are
P227GND ID129068780
P496ORCID iD0000-0003-4885-8471
P214VIAF ID74921442

P735given namePeterQ2793400
PeterQ2793400
P106occupationresearcherQ1650915
P21sex or gendermaleQ6581097

Reverse relations

author (P50)
Q3601638611q13 is a susceptibility locus for hormone receptor positive breast cancer
Q3031597014th St. Gallen International Breast Cancer Conference 2015: Evidence, Controversies, Consensus - Primary Therapy of Early Breast Cancer: Opinions Expressed by German Experts
Q3587156719p13.1 is a triple-negative-specific breast cancer susceptibility locus
Q338488952q36.3 is associated with prognosis for oestrogen receptor-negative breast cancer patients treated with chemotherapy
Q360214067q21-rs6964587 and breast cancer risk: an extended case-control study by the Breast Cancer Association Consortium
Q371698739q31.2-rs865686 as a susceptibility locus for estrogen receptor-positive breast cancer: evidence from the Breast Cancer Association Consortium
Q90622495A Phase II Study of Talazoparib after Platinum or Cytotoxic Nonplatinum Regimens in Patients with Advanced Breast Cancer and Germline BRCA1/2 Mutations (ABRAZO)
Q92609057A Small Hypoxia Signature Predicted pCR Response to Bevacizumab in the Neoadjuvant GeparQuinto Breast Cancer Trial
Q40486932A Standard Mammography Unit - Standard 3D Ultrasound Probe Fusion Prototype: First Results
Q59355837A Transcriptome-Wide Association Study Among 97,898 Women to Identify Candidate Susceptibility Genes for Epithelial Ovarian Cancer Risk
Q35755874A common variant at the TERT-CLPTM1L locus is associated with estrogen receptor-negative breast cancer
Q35957063A comprehensive evaluation of interaction between genetic variants and use of menopausal hormone therapy on mammographic density
Q33747778A genome-wide association study identifies a new ovarian cancer susceptibility locus on 9p22.2.
Q29417084A genome-wide association study identifies susceptibility loci for ovarian cancer at 2q31 and 8q24.
Q53650107A hybrid method towards automated nipple detection in 3D breast ultrasound images.
Q37619303A large-scale assessment of two-way SNP interactions in breast cancer susceptibility using 46,450 cases and 42,461 controls from the breast cancer association consortium
Q35089479A locus on 19p13 modifies risk of breast cancer in BRCA1 mutation carriers and is associated with hormone receptor-negative breast cancer in the general population
Q36435849A meta-analysis of genome-wide association studies of breast cancer identifies two novel susceptibility loci at 6q14 and 20q11.
Q45251774A multicentre phase II study on gefitinib in taxane- and anthracycline-pretreated metastatic breast cancer
Q92711687A network analysis to identify mediators of germline-driven differences in breast cancer prognosis
Q24626194A phase II trial to assess efficacy and safety of afatinib in extensively pretreated patients with HER2-negative metastatic breast cancer
Q90802186A randomized, window of opportunity study comparing the effects of the novel oral SERD AZD9496 with fulvestrant in patients with ER+ HER2- primary breast cancer
Q57305942A transcriptome-wide association study of 229,000 women identifies new candidate susceptibility genes for breast cancer
Q33947899ABCA transporter gene expression and poor outcome in epithelial ovarian cancer
Q37227494ABCB1 (MDR1) polymorphisms and ovarian cancer progression and survival: a comprehensive analysis from the Ovarian Cancer Association Consortium and The Cancer Genome Atlas
Q60043872ADSCs and adipocytes are the main producers in the autotaxin-lysophosphatidic acid axis of breast cancer and healthy mammary tissue in vitro
Q35432936AGR3 in breast cancer: prognostic impact and suitable serum-based biomarker for early cancer detection
Q61948755Abstract 3266: Expression quantitative trait locus analysis of triple negative breast cancer
Q62583469Abstract 5488: Utilizing a pathway based analysis of genome wide association data to identify biomarkers of toxicity in breast cancer patients
Q47347187Accuracy of radiological tumour size assessment and the risk for re-excision in a cohort of primary breast cancer patients
Q57072034Activity Levels of Tamoxifen Metabolites at the Estrogen Receptor and the Impact of Genetic Polymorphisms of Phase I and II Enzymes on Their Concentration Levels in Plasma
Q58695244Addition of triple negativity of breast cancer as an indicator for germline mutations in predisposing genes increases sensitivity of clinical selection criteria
Q38406780Adult body mass index and risk of ovarian cancer by subtype: a Mendelian randomization study
Q52647897Adult height is associated with increased risk of ovarian cancer: a Mendelian randomisation study.
Q36295107Advances in Breast Cancer - Looking Back over the Year
Q39437211Age- and Tumor Subtype-Specific Breast Cancer Risk Estimates for CHEK2*1100delC Carriers
Q39432829Akt and p53 are potential mediators of reduced mammary tumor growth by cloroquine and the mTOR inhibitor RAD001.
Q64231027An Electronic Patient-Reported Outcome Tool for the FACT-B (Functional Assessment of Cancer Therapy-Breast) Questionnaire for Measuring the Health-Related Quality of Life in Patients With Breast Cancer: Reliability Study
Q36073563An intergenic risk locus containing an enhancer deletion in 2q35 modulates breast cancer risk by deregulating IGFBP5 expression
Q42371458Analyses of germline variants associated with ovarian cancer survival identify functional candidates at the 1q22 and 19p12 outcome loci
Q64101095Analysis of GDF15 and IGFBP7 in Hyperemesis Gravidarum Support Causality
Q36831854Analysis of over 10,000 Cases finds no association between previously reported candidate polymorphisms and ovarian cancer outcome
Q89881422Anastrozole has an association between degree of estrogen suppression and outcomes in early breast cancer and is a ligand for estrogen receptor α
Q38667762Anti-Müllerian hormone (AMH) levels in premenopausal breast cancer patients treated with taxane-based adjuvant chemotherapy - A translational research project of the SUCCESS A study
Q61451341Antihyperglykämische Therapie bei Diabetes mellitus Typ 2
Q62774772Antihyperglykämische Therapie bei Diabetes mellitus Typ 2
Q34138371Are Certified Breast Centers Cost-Effective?
Q35142156Aspects of molecular diagnostics and therapy in obstetrics and gynecology
Q34613673Assessing interactions between the associations of common genetic susceptibility variants, reproductive history and body mass index with breast cancer risk in the breast cancer association consortium: a combined case-control study
Q30276986Assessing the genetic architecture of epithelial ovarian cancer histological subtypes
Q46687084Assessment of breast cancer tumor size depends on method, histopathology and tumor size itself*.
Q47399153Assessment of breast cancer tumour size using six different methods
Q35156876Assessment of hepatocyte growth factor in ovarian cancer mortality
Q35218520Assessment of variation in immunosuppressive pathway genes reveals TGFBR2 to be associated with prognosis of estrogen receptor-negative breast cancer after chemotherapy
Q37684409Assessment of variation in immunosuppressive pathway genes reveals TGFBR2 to be associated with risk of clear cell ovarian cancer
Q45979098Association analysis identifies 65 new breast cancer risk loci.
Q35006860Association between CYP2D6 polymorphisms and outcomes among women with early stage breast cancer treated with tamoxifen
Q33828680Association between a germline OCA2 polymorphism at chromosome 15q13.1 and estrogen receptor-negative breast cancer survival
Q24619808Association between endometriosis and risk of histological subtypes of ovarian cancer: a pooled analysis of case-control studies
Q40075679Association between mammographic density and pregnancies relative to age and BMI: a breast cancer case-only analysis
Q39388382Association of CA27.29 and Circulating Tumor Cells Before and at Different Times After Adjuvant Chemotherapy in Patients with Early-stage Breast Cancer - The SUCCESS Trial
Q37292963Association of ESR1 gene tagging SNPs with breast cancer risk
Q99417214Association of Pathological Complete Response with Long-Term Survival Outcomes in Triple-Negative Breast Cancer: A Meta-analysis
Q37684672Association of breast cancer risk with genetic variants showing differential allelic expression: Identification of a novel breast cancer susceptibility locus at 4q21.
Q37268494Association of genetic susceptibility variants for type 2 diabetes with breast cancer risk in women of European ancestry
Q96680596Association of genomic variants at the Human Leukocyte Antigen locus with cervical cancer risk, HPV status, and gene expression
Q114182713Association of germline genetic variants with breast cancer-specific survival in patient subgroups defined by clinic-pathological variables related to tumor biology and type of systemic treatment
Q53650262Association of mammographic density with hormone receptors in invasive breast cancers: results from a case-only study.
Q44287591Association of mammographic density with the proliferation marker Ki-67 in a cohort of patients with invasive breast cancer
Q41706112Association of molecular subtypes with breast cancer risk factors: a case-only analysis
Q56337548Association of p16 expression with prognosis varies across ovarian carcinoma histotypes: an Ovarian Tumor Tissue Analysis consortium study
Q39423088Association of vitamin D levels and risk of ovarian cancer: a Mendelian randomization study
Q35022847Associations of breast cancer risk factors with tumor subtypes: a pooled analysis from the Breast Cancer Association Consortium studies
Q35532898Associations of common variants at 1p11.2 and 14q24.1 (RAD51L1) with breast cancer risk and heterogeneity by tumor subtype: findings from the Breast Cancer Association Consortium
Q57056093Associations of obesity and circulating insulin and glucose with breast cancer risk: a Mendelian randomization analysis
Q33812789Attention, cognitive control and motivation in ADHD: Linking event-related brain potentials and DNA methylation patterns in boys at early school age.
Q57990746BRCA mutations and their influence on pathological complete response and prognosis in a clinical cohort of neoadjuvantly treated breast cancer patients
Q56968709BRCA1/2 Mutations and Bevacizumab in the Neoadjuvant Treatment of Breast Cancer: Response and Prognosis Results in Patients With Triple-Negative Breast Cancer From the GeparQuinto Study
Q38914005BRCA2 Hypomorphic Missense Variants Confer Moderate Risks of Breast Cancer
Q37002955BRCA2 Polymorphic Stop Codon K3326X and the Risk of Breast, Prostate, and Ovarian Cancers
Q36295142Biomarkers in Breast Cancer - An Update
Q35054455Biomarkers in Patients with Metastatic Breast Cancer and the PRAEGNANT Study Network
Q33997918Biomarkers in women's cancers, gynecology, and obstetrics
Q46115524Body mass index and breast cancer survival: a Mendelian randomization analysis
Q34209663Breast Cancer 2012 - New Aspects
Q37660589Breast Cancer Risk - From Genetics to Molecular Understanding of Pathogenesis
Q34201805Breast Cancer Risk - Genes, Environment and Clinics
Q35180940Breast Cancer Update 2014 - Focus on the Patient and the Tumour
Q57148656Breast Tumor Analysis Using Shifted-Excitation Raman Difference Spectroscopy (SERDS)
Q50033721Breast cancer in young women: do BRCA1 or BRCA2 mutations matter?
Q43122429Breast cancer risk assessment in a mammography screening program and participation in the IBIS-II chemoprevention trial
Q35940158Breast cancer risk variants at 6q25 display different phenotype associations and regulate ESR1, RMND1 and CCDC170.
Q39978884Breast volumetry using a three-dimensional surface assessment technique
Q52849107CA27.29 as a tumour marker for risk evaluation and therapy monitoring in primary breast cancer patients.
Q36449203CHEK2*1100delC heterozygosity in women with breast cancer associated with early death, breast cancer-specific death, and increased risk of a second breast cancer
Q36419325CYP19A1 fine-mapping and Mendelian randomization: estradiol is causal for endometrial cancer
Q34793437CYP2B6*6 is associated with increased breast cancer risk
Q37524058CYP2D6 genotype and adjuvant tamoxifen: meta-analysis of heterogeneous study populations
Q33591915CYP2D6 polymorphisms as predictors of outcome in breast cancer patients treated with tamoxifen: expanded polymorphism coverage improves risk stratification
Q28385765Candidate locus analysis of the TERT-CLPTM1L cancer risk region on chromosome 5p15 identifies multiple independent variants associated with endometrial cancer risk
Q43121689Capecitabine in addition to anthracycline- and taxane-based neoadjuvant treatment in patients with primary breast cancer: phase III GeparQuattro study
Q53172588Changes in satisfaction in patients with gynaecological and breast malignancies: an analysis with the Socio-Economic Satisfaction and Quality of Life questionnaire.
Q54196115Changes in serum levels of miR-21, miR-210, and miR-373 in HER2-positive breast cancer patients undergoing neoadjuvant therapy: a translational research project within the Geparquinto trial.
Q100392948Characteristics and Clinical Outcome of Breast Cancer Patients with Asymptomatic Brain Metastases
Q36245595Characterizing mammographic images by using generic texture features
Q57098750Children of Prenatally Depressed Mothers: Externalizing and Internalizing Symptoms are Accompanied by Reductions in Specific Social-Emotional Competencies
Q37858099Chlamydia trachomatis infection as a risk factor for infertility among women in Ghana, West Africa.
Q47150180Circulating Tumour Cells, Circulating Tumour DNA and Circulating MicroRNA in Metastatic Breast Carcinoma - What is the Role of Liquid Biopsy in Breast Cancer?
Q34221705Circulating miR-148b and miR-133a as biomarkers for breast cancer detection
Q21134914Circulating micro-RNAs as potential blood-based markers for early stage breast cancer detection
Q33958981Circulating tumor cells predict survival in early average-to-high risk breast cancer patients
Q35782435Cis-eQTL analysis and functional validation of candidate susceptibility genes for high-grade serous ovarian cancer
Q45746480Clinical validation of genetic variants associated with in vitro chemotherapy-related lymphoblastoid cell toxicity
Q94486442Combined associations of a polygenic risk score and classical risk factors with breast cancer risk
Q35668946Common Genetic Variation In Cellular Transport Genes and Epithelial Ovarian Cancer (EOC) Risk
Q36490507Common Genetic Variation in Circadian Rhythm Genes and Risk of Epithelial Ovarian Cancer (EOC).
Q34126314Common alleles in candidate susceptibility genes associated with risk and development of epithelial ovarian cancer
Q35891162Common breast cancer susceptibility loci are associated with triple-negative breast cancer
Q36600605Common breast cancer susceptibility variants in LSP1 and RAD51L1 are associated with mammographic density measures that predict breast cancer risk
Q35794653Common germline polymorphisms associated with breast cancer-specific survival
Q34379032Common non-synonymous SNPs associated with breast cancer susceptibility: findings from the Breast Cancer Association Consortium
Q29417145Common variants at 19p13 are associated with susceptibility to ovarian cancer
Q36255665Common variants at the CHEK2 gene locus and risk of epithelial ovarian cancer
Q31082788Comparison of 6q25 breast cancer hits from Asian and European Genome Wide Association Studies in the Breast Cancer Association Consortium (BCAC)
Q35054469Comparison of Sonography versus Digital Breast Tomosynthesis to Locate Intramammary Marker Clips
Q62583467Competitive analysis of pregnancy associated HLA-proteins in trophoblast and breast cancer tissue
Q36026731Comprehensive genetic assessment of the ESR1 locus identifies a risk region for endometrial cancer
Q39256294Comprehensive visualization of paresthesia in breast cancer survivors
Q31107007Computerized patient identification for the EMBRACA clinical trial using real-time data from the PRAEGNANT network for metastatic breast cancer patients
Q34181322Confirmation of 5p12 as a susceptibility locus for progesterone-receptor-positive, lower grade breast cancer
Q34342248Consortium analysis of gene and gene-folate interactions in purine and pyrimidine metabolism pathways with ovarian carcinoma risk
Q57278898Correction: Comparison of 6q25 Breast Cancer Hits from Asian and European Genome Wide Association Studies in the Breast Cancer Association Consortium (BCAC)
Q46494349Correlates of the desire for improved cosmetic results after breast-conserving therapy and mastectomy in breast cancer patients
Q37855560Correlation of high-risk human papilloma viruses but not of herpes viruses or Chlamydia trachomatis with endometriosis lesions
Q37452184Correlation of histological and macroscopic findings in peritoneal endometriosis
Q33775316Correlation of mammographic density and serum calcium levels in patients with primary breast cancer
Q34278775Cost-Benefit Analysis of Endocrine Therapy in the Adjuvant Setting for Postmenopausal Patients with Hormone Receptor-Positive Breast Cancer, Based on Survival Data and Future Prices for Generic Drugs in the Context of the German Health Care System
Q101216461Cross-cancer genome-wide association study of endometrial cancer and epithelial ovarian cancer identifies genetic risk regions associated with risk of both cancers
Q36540420DNA methylation outliers in normal breast tissue identify field defects that are enriched in cancer
Q37685729DNA mismatch repair gene MSH6 implicated in determining age at natural menopause
Q54516956Definition and impact of pathologic complete response on prognosis after neoadjuvant chemotherapy in various intrinsic breast cancer subtypes.
Q48635565Delivery mode and the course of pre- and postpartum depression.
Q36069885Detection of circulating tumor cells using manually performed immunocytochemistry (MICC) does not correlate with outcome in patients with early breast cancer - Results of the German SUCCESS-A- trial
Q35624654Development and Validation of a Standardized Questionnaire and Standardized Diary for Use in Integrative Medicine Consultations in Gynecologic Oncology
Q96590073Development and validation of the gene-expression Predictor of high-grade-serous Ovarian carcinoma molecular subTYPE (PrOTYPE)
Q64982162Development of central nervous system metastases as a first site of metastatic disease in breast cancer patients treated in the neoadjuvant trials GeparQuinto and GeparSixto.
Q64980662Diagnosis and Therapy of Triple-Negative Breast Cancer (TNBC) - Recommendations for Daily Routine Practice.
Q47952423Did you drink alcohol during pregnancy? Inaccuracy and discontinuity of women's self-reports: On the way to establish meconium ethyl glucuronide (EtG) as a biomarker for alcohol consumption during pregnancy
Q50868171Digit ratio (2D:4D) and behavioral symptoms in primary-school aged boys.
Q41506407Documentation Time and Effort and Associated Resources for Patients with Primary Breast Cancer from Diagnosis to End of Follow-Up - Results of a Multicentre Validation
Q43924266Dose-Response Association of CD8+ Tumor-Infiltrating Lymphocytes and Survival Time in High-Grade Serous Ovarian Cancer.
Q39936321Early aberrant insulin-like growth factor signaling in the progression to endometrial carcinoma is augmented by tamoxifen
Q47273243Effects of prenatal alcohol consumption on cognitive development and ADHD-related behaviour in primary-school age: a multilevel study based on meconium ethyl glucuronide
Q40273075Effects of the antiestrogens tamoxifen and raloxifene on the estrogen receptor transactivation machinery.
Q56967384Efficacy and safety of everolimus plus exemestane in postmenopausal women with hormone receptor-positive, human epidermal growth factor receptor 2-negative locally advanced or metastatic breast cancer etc.
Q57461653Efficacy of neoadjuvant pertuzumab in addition to chemotherapy and trastuzumab in routine clinical treatment of patients with primary breast cancer: a multicentric analysis
Q22250928Einfluss des mütterlichen Alkoholkonsums während der Schwangerschaft auf die Entwicklung von ADHS beim Kind
Q38636290Electronic-Based Patient-Reported Outcomes: Willingness, Needs, and Barriers in Adjuvant and Metastatic Breast Cancer Patients.
Q54953677Elevated serum RAS p21 is an independent prognostic factor in metastatic breast cancer.
Q52681182Endocrine Treatment with 2 Years of Tamoxifen versus 2 Years of Exemestane in Postmenopausal Patients with High-Risk Early Breast Cancer and Persisting Circulating Tumor Cells - First Results of the SUCCESS C Endocrine Treatment Sub-Study.
Q35815412Endometriosis as a risk factor for ovarian or endometrial cancer - results of a hospital-based case-control study
Q38720533Enrichment of putative PAX8 target genes at serous epithelial ovarian cancer susceptibility loci
Q24633316Epigenetic analysis leads to identification of HNF1B as a subtype-specific susceptibility gene for ovarian cancer
Q36487146Epithelial-Mesenchymal Transition (EMT) Gene Variants and Epithelial Ovarian Cancer (EOC) Risk
Q42649791Erratum to: The integrative epigenomic-transcriptomic landscape of ER positive breast cancer
Q57319395Erratum: Corrigendum: Common variants at 19p13 are associated with susceptibility to ovarian cancer
Q57202568Erratum: Corrigendum: Genome-wide association study identifies multiple loci associated with both mammographic density and breast cancer risk
Q33932856Estrogen receptor beta rs1271572 polymorphism and invasive ovarian carcinoma risk: pooled analysis within the Ovarian Cancer Association Consortium
Q36966218Evaluating the ovarian cancer gonadotropin hypothesis: a candidate gene study
Q37389684Evaluation of Newly Adapted Clip Marker System in Ultrasound-Guided Core Needle Biopsy for Suspicion of Breast Cancer
Q34764981Evaluation of Therapy Management and Patient Compliance in Postmenopausal Patients with Hormone Receptor-positive Breast Cancer Receiving Letrozole Treatment: The EvaluateTM Study
Q37709871Evaluation of a Marker Clip System in Sonographically Guided Core Needle Biopsy for Breast Cancer Localization Before and After Neoadjuvant Chemotherapy
Q43697261Evaluation of mathematical models for breast cancer risk assessment in routine clinical use.
Q47130842Evaluation of serum epidermal growth factor receptor (EGFR) in correlation to circulating tumor cells in patients with metastatic breast cancer
Q91265555Evaluation of soluble carbonic anhydrase IX as predictive marker for efficacy of bevacizumab: A biomarker analysis from the geparquinto phase III neoadjuvant breast cancer trial
Q35653910Evaluation of variation in the phosphoinositide-3-kinase catalytic subunit alpha oncogene and breast cancer risk
Q34687073Evidence for a time-dependent association between FOLR1 expression and survival from ovarian carcinoma: implications for clinical testing. An Ovarian Tumour Tissue Analysis consortium study
Q36720821Evidence of gene-environment interactions between common breast cancer susceptibility loci and established environmental risk factors
Q35064451Evidence that breast cancer risk at the 2q35 locus is mediated through IGFBP5 regulation
Q37342144Evidence that the 5p12 Variant rs10941679 Confers Susceptibility to Estrogen-Receptor-Positive Breast Cancer through FGF10 and MRPS30 Regulation
Q37631322Expression of neuroendocrine markers in different molecular subtypes of breast carcinoma
Q52872813Expression of secreted protein acidic and rich in cysteine (SPARC) in breast cancer and response to neoadjuvant chemotherapy.
Q37594336FGF receptor genes and breast cancer susceptibility: results from the Breast Cancer Association Consortium
Q30313653Factors Influencing Decision-Making for or against Adjuvant and Neoadjuvant Chemotherapy in Postmenopausal Hormone Receptor-Positive Breast Cancer Patients in the EvAluate-TM Study
Q45006117Factors influencing breast changes after pregnancy
Q31150676FemZone trial: a randomized phase II trial comparing neoadjuvant letrozole and zoledronic acid with letrozole in primary breast cancer patients
Q49796329Filtration based assessment of CTCs and CellSearch® based assessment are both powerful predictors of prognosis for metastatic breast cancer patients.
Q50748345Financial viability of perinatal centers in the longer term, taking legislative requirements into account. An examination of the cost-revenue structure of a Level I perinatal center.
Q44318881Financing of certified centers: a willingness-to-pay analysis
Q37236216Fine scale mapping of the 17q22 breast cancer locus using dense SNPs, genotyped within the Collaborative Oncological Gene-Environment Study (COGs).
Q36111237Fine-Mapping of the 1p11.2 Breast Cancer Susceptibility Locus
Q35524465Fine-mapping identifies two additional breast cancer susceptibility loci at 9q31.2.
Q61230414Fine-mapping of 150 breast cancer risk regions identifies 178 high confidence target genes
Q92480972Fine-mapping of 150 breast cancer risk regions identifies 191 likely target genes
Q35063160Fine-mapping of the HNF1B multicancer locus identifies candidate variants that mediate endometrial cancer risk
Q39844032Fine-scale mapping of 8q24 locus identifies multiple independent risk variants for breast cancer
Q36248936Fine-scale mapping of the 4q24 locus identifies two independent loci associated with breast cancer risk
Q34903062Fine-scale mapping of the 5q11.2 breast cancer locus reveals at least three independent risk variants regulating MAP3K1.
Q37367871Fine-scale mapping of the FGFR2 breast cancer risk locus: putative functional variants differentially bind FOXA1 and E2F1.
Q37002930Five endometrial cancer risk loci identified through genome-wide association analysis
Q34979715Five polymorphisms and breast cancer risk: results from the Breast Cancer Association Consortium
Q36295117Full Field Digital Mammography (FFDM) versus CMOS Technology versus Tomosynthesis (DBT) - Which System Increases the Quality of Intraoperative Imaging?
Q37395450Full Field Digital Mammography (FFDM) versus CMOS Technology, Specimen Radiography System (SRS) and Tomosynthesis (DBT) - Which System Can Optimise Surgical Therapy?
Q36124728Functional mechanisms underlying pleiotropic risk alleles at the 19p13.1 breast-ovarian cancer susceptibility locus
Q36742577Functional variants at the 11q13 risk locus for breast cancer regulate cyclin D1 expression through long-range enhancers
Q36956156GWAS meta-analysis and replication identifies three new susceptibility loci for ovarian cancer
Q55037331Galactography with Tomosynthesis Technique (Galactomosynthesis) - Renaissance of a Method?
Q100426680Gene expression signatures of BRCAness and tumor inflammation define subgroups of early-stage hormone receptor-positive breast cancer patients
Q48361014Gene panel sequencing in familial breast/ovarian cancer patients identifies multiple novel mutations also in genes others than BRCA1/2.
Q40137431Gene-environment interactions involving functional variants: Results from the Breast Cancer Association Consortium
Q41040904Genetic Breast Cancer Susceptibility Variants and Prognosis in the Prospectively Randomized SUCCESS A Study
Q62583319Genetic Data from Nearly 63,000 Women of European Descent Predicts DNA Methylation Biomarkers and Epithelial Ovarian Cancer Risk
Q37389405Genetic Risk Score Mendelian Randomization Shows that Obesity Measured as Body Mass Index, but not Waist:Hip Ratio, Is Causal for Endometrial Cancer
Q115209620Genetic analyses of gynecological disease identify genetic relationships between uterine fibroids and endometrial cancer, and a novel endometrial cancer genetic risk region at the WNT4 1p36.12 locus
Q37739048Genetic modifiers of CHEK2*1100delC-associated breast cancer risk
Q54940815Genetic overlap between endometriosis and endometrial cancer: evidence from cross-disease genetic correlation and GWAS meta-analyses.
Q35925620Genetic predisposition to ductal carcinoma in situ of the breast
Q35151684Genetic predisposition to in situ and invasive lobular carcinoma of the breast
Q45968079Genetic risk factors for ovarian cancer and their role for endometriosis risk.
Q46721561Genetic variants in VEGF pathway genes in neoadjuvant breast cancer patients receiving bevacizumab: Results from the randomized phase III GeparQuinto study
Q37679549Genetic variants in the genes of the stress hormone signalling pathway and depressive symptoms during and after pregnancy
Q48657862Genetic variants in the tryptophan hydroxylase 2 gene (TPH2) and depression during and after pregnancy.
Q35179897Genetic variation at CYP3A is associated with age at menarche and breast cancer risk: a case-control study
Q34378972Genetic variation in mitotic regulatory pathway genes is associated with breast tumor grade
Q36422109Genetic variation in the immunosuppression pathway genes and breast cancer susceptibility: a pooled analysis of 42,510 cases and 40,577 controls from the Breast Cancer Association Consortium
Q30000080Genetically Predicted Body Mass Index and Breast Cancer Risk: Mendelian Randomization Analyses of Data from 145,000 Women of European Descent
Q28388497Genome-Wide Meta-Analyses of Breast, Ovarian, and Prostate Cancer Association Studies Identify Multiple New Susceptibility Loci Shared by at Least Two Cancer Types
Q36218993Genome-wide Analysis Identifies Novel Loci Associated with Ovarian Cancer Outcomes: Findings from the Ovarian Cancer Association Consortium
Q36842233Genome-wide association analysis identifies three new breast cancer susceptibility loci
Q35996692Genome-wide association analysis of more than 120,000 individuals identifies 15 new susceptibility loci for breast cancer
Q63681757Genome-wide association and transcriptome studies identify target genes and risk loci for breast cancer
Q24622610Genome-wide association studies identify four ER negative-specific breast cancer risk loci
Q29417100Genome-wide association study identifies 25 known breast cancer susceptibility loci as risk factors for triple-negative breast cancer
Q95329367Genome-wide association study identifies 32 novel breast cancer susceptibility loci from overall and subtype-specific analyses
Q29417135Genome-wide association study identifies a common variant associated with risk of endometrial cancer
Q36024614Genome-wide association study identifies a possible susceptibility locus for endometrial cancer
Q35061252Genome-wide association study identifies multiple loci associated with both mammographic density and breast cancer risk
Q64040390Genome-wide association study of germline variants and breast cancer-specific mortality
Q33778612Genome-wide association study of subtype-specific epithelial ovarian cancer risk alleles using pooled DNA.
Q59566871Genomic analyses for age at menarche identify 389 independent signals and indicate BMI-independent effects of puberty timing on cancer susceptibility
Q38823212Genomic analyses identify hundreds of variants associated with age at menarche and support a role for puberty timing in cancer risk
Q38373098Germline Mutation Status, Pathological Complete Response, and Disease-Free Survival in Triple-Negative Breast Cancer: Secondary Analysis of the GeparSixto Randomized Clinical Trial
Q88693944Germline genome-wide association studies in women receiving neoadjuvant chemotherapy with or without bevacizumab
Q36916243Germline polymorphisms in an enhancer of PSIP1 are associated with progression-free survival in epithelial ovarian cancer
Q45733546Germline variation in ADAMTSL1 is associated with prognosis following breast cancer treatment in young women
Q40090312Grating-based darkfield imaging of human breast tissue
Q36903047HER2 and ESR1 mRNA expression levels and response to neoadjuvant trastuzumab plus chemotherapy in patients with primary breast cancer
Q46188099HER2 and TOP2A amplification in a hospital-based cohort of breast cancer patients: associations with patient and tumor characteristics
Q99728010HLA-G and HLA-F protein isoform expression in breast cancer patients receiving neoadjuvant treatment
Q26996601Health Services Research and Health Economy - Quality Care Training in Gynaecology, with Focus On Gynaecological Oncology
Q48086218Health utilities in gynecological oncology and mastology in Germany
Q37341647Health-related Quality of Life in Metastatic and Adjuvant Breast Cancer Patients
Q36276540Height and Breast Cancer Risk: Evidence From Prospective Studies and Mendelian Randomization
Q36311502Hereditary breast and ovarian cancer: review and future perspectives
Q101570878Heregulin (HRG) assessment for clinical trial eligibility testing in a molecular registry (PRAEGNANT) in Germany
Q54566127Higher efficacy of letrozole in combination with trastuzumab compared to letrozole monotherapy as first-line treatment in patients with HER2-positive, hormone-receptor-positive metastatic breast cancer - results of the eLEcTRA trial.
Q40060927History of Comorbidities and Survival of Ovarian Cancer Patients, Results from the Ovarian Cancer Association Consortium
Q35815464Hormone Therapy and its Effect on the Prognosis in Breast Cancer Patients
Q43694432Hormone replacement therapy and prognosis in ovarian cancer patients
Q35102646Identification and characterization of novel associations in the CASP8/ALS2CR12 region on chromosome 2 with breast cancer risk
Q37006170Identification and molecular characterization of a new ovarian cancer susceptibility locus at 17q21.31.
Q30252854Identification of 12 new susceptibility loci for different histotypes of epithelial ovarian cancer
Q36720814Identification of a BRCA2-specific modifier locus at 6p24 related to breast cancer risk
Q112717190Identification of a Locus Near ULK1 Associated With Progression-Free Survival in Ovarian Cancer
Q59291228Identification of a genetic variant associated with treatment outcome in ovarian cancer: the potential role of cholesterol metabolism as a determinant of response to chemotherapy
Q36859142Identification of four novel susceptibility loci for oestrogen receptor negative breast cancer
Q36086247Identification of independent association signals and putative functional variants for breast cancer risk through fine-scale mapping of the 12p11 locus
Q34038964Identification of new genetic susceptibility loci for breast cancer through consideration of gene-environment interactions
Q57170142Identification of nine new susceptibility loci for endometrial cancer
Q36014067Identification of novel genetic markers of breast cancer survival
Q35541663Identification of six new susceptibility loci for invasive epithelial ovarian cancer
Q46103372Identification of ten variants associated with risk of estrogen-receptor-negative breast cancer
Q50866974Impact of disease progression on health-related quality of life in patients with metastatic breast cancer in the PRAEGNANT breast cancer registry.
Q38606464Implementation and Feasibility of Electronic Patient-Reported Outcome (ePRO) Data Entry in the PRAEGNANT Real-Time Advanced and Metastatic Breast Cancer Registry
Q114184688Incorporating progesterone receptor expression into the PREDICT breast prognostic model
Q48122440Infarction of primary sensorimotor cortex impairs pain perception
Q47318223Influence of mammographic density on the diagnostic accuracy of tumor size assessment and association with breast cancer tumor characteristics
Q50089754Influence of patient and tumor characteristics on early therapy persistence with letrozole in postmenopausal women with early breast cancer: results of the prospective Evaluate-TM study with 3941 patients.
Q92942975Influence of patient and tumor characteristics on therapy persistence with letrozole in postmenopausal women with advanced breast cancer: results of the prospective observational EvAluate-TM study
Q52572827Influence of side-effects on early therapy persistence with letrozole in post-menopausal patients with early breast cancer: Results of the prospective EvAluate-TM study.
Q34996647Inherited mutations in 17 breast cancer susceptibility genes among a large triple-negative breast cancer cohort unselected for family history of breast cancer
Q37684424Inherited variants affecting RNA editing may contribute to ovarian cancer susceptibility: results from a large-scale collaboration
Q35104068Inherited variants in the inner centromere protein (INCENP) gene of the chromosomal passenger complex contribute to the susceptibility of ER-negative breast cancer
Q35133135Inhibition of adhesion, proliferation, and invasion of primary endometriosis and endometrial stromal and ovarian carcinoma cells by a nonhyaluronan adhesion barrier gel.
Q39775283Inhibition of hyperalgesia by conditioning electrical stimulation in a human pain model
Q41012013Initial Treatment of Patients with Primary Breast Cancer: Evidence, Controversies, Consensus: Spectrum of Opinion of German Specialists at the 15th International St. Gallen Breast Cancer Conference (Vienna 2017).
Q62774275Insulintherapie bei Diabetes mellitus
Q62774815Insulintherapie bei Diabetes mellitus
Q52857952Integrated Analysis of PTEN and p4EBP1 Protein Expression as Predictors for pCR in HER2-Positive Breast Cancer.
Q33390705Integrating bevacizumab, everolimus, and lapatinib into current neoadjuvant chemotherapy regimen for primary breast cancer. Safety results of the GeparQuinto trial
Q58124814Interdisciplinary Screening, Diagnosis, Therapy and Follow-up of Breast Cancer. Guideline of the DGGG and the DKG (S3-Level, AWMF Registry Number 032/045OL, December 2017) - Part 1 with Recommendations for the Screening, Diagnosis and Therapy of Brea
Q39390636Interest in Integrative Medicine Among Postmenopausal Hormone Receptor-Positive Breast Cancer Patients in the EvAluate-TM Study
Q35576242Invasive Breast Cancer: Recognition of Molecular Subtypes
Q34898735Investigation of gene-environment interactions between 47 newly identified breast cancer susceptibility loci and environmental risk factors
Q64279327Joint association of mammographic density adjusted for age and body mass index and polygenic risk score with breast cancer risk
Q47190168Joint associations of a polygenic risk score and environmental risk factors for breast cancer in the Breast Cancer Association Consortium
Q44303312Ki-67 as a prognostic molecular marker in routine clinical use in breast cancer patients
Q44258071Ki67 measured after neoadjuvant chemotherapy for primary breast cancer
Q34074094Ki67, chemotherapy response, and prognosis in breast cancer patients receiving neoadjuvant treatment
Q35745601Knowledge and attitudes regarding medical research studies among patients with breast cancer and gynecological diseases
Q52890142Lapatinib versus trastuzumab in combination with neoadjuvant anthracycline-taxane-based chemotherapy (GeparQuinto, GBG 44): a randomised phase 3 trial.
Q57191573Large-Scale Genomic Analyses Link Reproductive Aging to Hypothalamic Signaling, Breast Cancer Susceptibility, and BRCA1-Mediated DNA Repair
Q37725393Large-scale evaluation of common variation in regulatory T cell-related genes and ovarian cancer outcome
Q28267893Large-scale genomic analyses link reproductive aging to hypothalamic signaling, breast cancer susceptibility and BRCA1-mediated DNA repair
Q29416989Large-scale genotyping identifies 41 new loci associated with breast cancer risk
Q46671490Long-term disease-free survival after hormonal therapy of a patient with recurrent low grade endometrial stromal sarcoma: a case report
Q35119701Low penetrance breast cancer susceptibility loci are associated with specific breast tumor subtypes: findings from the Breast Cancer Association Consortium
Q51057785Lymphedema in breast cancer survivors: assessment and information provision in a specialized breast unit.
Q125948696MUC1 (CA27.29) before and after Chemotherapy and Prognosis in High-Risk Early Breast Cancer Patients
Q45381957Major histocompatibility complex class II polymorphisms are associated with the development of anti-resorptive agent-induced osteonecrosis of the jaw.
Q37382835Mammographic Density and Prediction of Nodal Status in Breast Cancer Patients
Q39622978Mammographic density is the main correlate of tumors detected on ultrasound but not on mammography
Q37700515Meconium indicators of maternal alcohol abuse during pregnancy and association with patient characteristics
Q114182490Mendelian randomisation study of smoking exposure in relation to breast cancer risk
Q98772941Mendelian randomization analyses suggest a role for cholesterol in the development of endometrial cancer
Q36333368Meta-analysis of genome-wide association studies identifies common susceptibility polymorphisms for colorectal and endometrial cancer near SH2B3 and TSHZ1.
Q34497352MicroRNA related polymorphisms and breast cancer risk
Q61446881Mindfulness-based Stress Reduction in Pregnancy: an App-Based Programme to Improve the Health of Mothers and Children (MINDFUL/PMI Study)
Q34123806Missense variants in ATM in 26,101 breast cancer cases and 29,842 controls
Q37798407Mitomycin C in patients with gynecological malignancies
Q113695636Molecular Subtyping of Invasive Breast Cancer Using a PAM50-Based Multigene Expression Test-Comparison with Molecular-Like Subtyping by Tumor Grade/Immunohistochemistry and Influence on Oncologist’s Decision on Systemic Therapy in a Real-World Setti
Q34542660Molecular profiling of single circulating tumor cells with diagnostic intention
Q36897003Multiple independent variants at the TERT locus are associated with telomere length and risks of breast and ovarian cancer
Q93064583Mutational Diversity and Therapy Response in Breast Cancer: A Sequencing Analysis in the Neoadjuvant GeparSepto Trial
Q52675313MyD88 and TLR4 Expression in Epithelial Ovarian Cancer.
Q42363504Neoadjuvant Treatment of Breast Cancer - Advances and Limitations
Q53752984Neoadjuvant bevacizumab and anthracycline-taxane-based chemotherapy in 678 triple-negative primary breast cancers; results from the geparquinto study (GBG 44).
Q33415041Neoadjuvant carboplatin in patients with triple-negative and HER2-positive early breast cancer (GeparSixto; GBG 66): a randomised phase 2 trial
Q54534083Neoadjuvant chemotherapy and bevacizumab for HER2-negative breast cancer.
Q46634705Neoadjuvant chemotherapy in breast cancer: which diagnostic procedures can be used?
Q33406730Neoadjuvant chemotherapy with paclitaxel and everolimus in breast cancer patients with non-responsive tumours to epirubicin/cyclophosphamide (EC) ± bevacizumab - results of the randomised GeparQuinto study (GBG 44).
Q43121691Neoadjuvant treatment with trastuzumab in HER2-positive breast cancer: results from the GeparQuattro study
Q26799669Network-Based Integration of GWAS and Gene Expression Identifies a HOX-Centric Network Associated with Serous Ovarian Cancer Risk
Q53254794New diagnostic criteria in real-time elastography for the assessment of breast lesions.
Q30275832No Evidence That Genetic Variation in the Myeloid-Derived Suppressor Cell Pathway Influences Ovarian Cancer Survival
Q30374367No clinical utility of KRAS variant rs61764370 for ovarian or breast cancer.
Q37079859No evidence that protein truncating variants in BRIP1 are associated with breast cancer risk: implications for gene panel testing
Q35752042Novel Associations between Common Breast Cancer Susceptibility Variants and Risk-Predicting Mammographic Density Measures
Q36027025Obesity and survival among women with ovarian cancer: results from the Ovarian Cancer Association Consortium
Q39007087Optimizing R with SparkR on a commodity cluster for biomedical research
Q52805657Outcome after neoadjuvant chemotherapy in elderly breast cancer patients - a pooled analysis of individual patient data from eight prospectively randomized controlled trials.
Q48030360Outcome after neoadjuvant chemotherapy in estrogen receptor-positive and progesterone receptor-negative breast cancer patients: a pooled analysis of individual patient data from ten prospectively randomized controlled neoadjuvant trials
Q31108673Overexpression of SERBP1 (Plasminogen activator inhibitor 1 RNA binding protein) in human breast cancer is correlated with favourable prognosis
Q39827385Oxytocin receptor DNA methylation in postpartum depression
Q28584533PALB2, CHEK2 and ATM rare variants and cancer risk: data from COGS
Q47143943PHIP - a novel candidate breast cancer susceptibility locus on 6q14.1.
Q52874022PIK3CA mutations are associated with lower rates of pathologic complete response to anti-human epidermal growth factor receptor 2 (her2) therapy in primary HER2-overexpressing breast cancer.
Q100312898PIWI-Like 1 and PIWI-Like 2 Expression in Breast Cancer
Q36184231PREDICT Plus: development and validation of a prognostic model for early breast cancer that includes HER2.
Q52897434PREPARE trial: a randomized phase III trial comparing preoperative, dose-dense, dose-intensified chemotherapy with epirubicin, paclitaxel and CMF versus a standard-dosed epirubicin/cyclophosphamide followed by paclitaxel ± darbepoetin alfa in primar
Q52897474PREPARE trial: a randomized phase III trial comparing preoperative, dose-dense, dose-intensified chemotherapy with epirubicin, paclitaxel, and CMF versus a standard-dosed epirubicin-cyclophosphamide followed by paclitaxel with or without darbepoetin
Q33488582Pain perception and detailed visual pain mapping in breast cancer survivors
Q34289136Parent-of-origin-specific allelic associations among 106 genomic loci for age at menarche
Q52893849Pathologic complete response after neoadjuvant chemotherapy plus trastuzumab predicts favorable survival in human epidermal growth factor receptor 2-overexpressing breast cancer: results from the TECHNO trial of the AGO and GBG study groups.
Q38188183Pathological complete response and long-term clinical benefit in breast cancer: the CTNeoBC pooled analysis
Q112572520Pathology of Tumors Associated With Pathogenic Germline Variants in 9 Breast Cancer Susceptibility Genes
Q52723445Pathway-Based Analysis of Genome-Wide Association Data Identified SNPs in HMMR as Biomarker for Chemotherapy- Induced Neutropenia in Breast Cancer Patients.
Q37307937Patient survival and tumor characteristics associated with CHEK2:p.I157T - findings from the Breast Cancer Association Consortium
Q39285061Patient-reported outcomes (PRO) focused on adverse events (PRO-AEs) in adjuvant and metastatic breast cancer: clinical and translational implications
Q51121776Patients' attitudes to totally implantable venous access port systems for gynecological or breast malignancies.
Q34209634Percent Mammographic Density and Dense Area as Risk Factors for Breast Cancer
Q46757183Phase III trial of sunitinib in combination with capecitabine versus capecitabine monotherapy for the treatment of patients with pretreated metastatic breast cancer
Q34209656Pilot Study on the Detection of Simulated Lesions Using a 2D and 3D Digital Full-Field Mammography System with a Newly Developed High Resolution Detector Based on Two Shifts of a-Se
Q62583133Polygenic Risk Scores for Prediction of Breast Cancer and Breast Cancer Subtypes
Q42985583Polymorphism in HTR3D shows different risks for acute chemotherapy-induced vomiting after anthracycline chemotherapy
Q36066735Polymorphisms in a Putative Enhancer at the 10q21.2 Breast Cancer Risk Locus Regulate NRBF2 Expression
Q46158039Polymorphisms in estrogen metabolism and estrogen pathway genes and the risk of miscarriage
Q36915870Polymorphisms in inflammation pathway genes and endometrial cancer risk
Q42013702Polymorphisms in the RANK/RANKL genes and their effect on bone specific prognosis in breast cancer patients
Q34767999Polymorphisms in the novel serotonin receptor subunit gene HTR3C show different risks for acute chemotherapy-induced vomiting after anthracycline chemotherapy
Q40142509Pooled Analysis of the Prognostic Relevance of Circulating Tumor Cells in Primary Breast Cancer
Q36966258Population distribution of lifetime risk of ovarian cancer in the United States
Q41011976Predicting Triple-Negative Breast Cancer Subtype Using Multiple Single Nucleotide Polymorphisms for Breast Cancer Risk and Several Variable Selection Methods
Q92055460Prediction and clinical utility of a contralateral breast cancer risk model
Q36583004Prediction of breast cancer risk based on profiling with common genetic variants
Q58101133Prediction of pathological complete response and prognosis in patients with neoadjuvant treatment for triple-negative breast cancer
Q36299086Predictive value of HER2 serum levels in patients treated with lapatinib or trastuzumab -- a translational project in the neoadjuvant GeparQuinto trial
Q92551866Preexisting musculoskeletal burden and its development under letrozole treatment in early breast cancer patients
Q47755445Prenatal and adult androgen activities in alcohol dependence
Q57476250Presence of Circulating Tumor Cells in High-Risk Early Breast Cancer During Follow-Up and Prognosis
Q38964883Prevalence of Circulating Tumor Cells After Adjuvant Chemotherapy With or Without Anthracyclines in Patients With HER2-negative, Hormone Receptor-positive Early Breast Cancer
Q30316383Primary Therapy of Patients with Early Breast Cancer: Evidence, Controversies, Consensus: Opinions of German Specialists to the 14th St. Gallen International Breast Cancer Conference 2015 (Vienna 2015).
Q92346464Prognostic effect of Ki-67 in common clinical subgroups of patients with HER2-negative, hormone receptor-positive early breast cancer
Q36924426Prognostic impact of circulating tumor cells assessed with the CellSearch System™ and AdnaTest Breast™ in metastatic breast cancer patients: the DETECT study
Q42512310Prognostic molecular markers and neoadjuvant therapy response in anthracycline-treated breast cancer patients
Q45756790Prognostic relevance of Ki-67 in the primary tumor for survival after a diagnosis of distant metastasis
Q45408422Prognostic significance of serum antibodies to HPV-16 L1 virus-like particles in patients with invasive cervical cancer
Q45393694Prognostic significance of the detection of human papilloma virus L1 protein in smears of mild to moderate cervical intraepithelial lesions
Q100746843Progression-Free Survival and Overall Survival in Patients with Advanced HER2-Positive Breast Cancer Treated with Trastuzumab Emtansine (T-DM1) after Previous Treatment with Pertuzumab
Q54574341Proliferation and cell-cell fusion of endometrial carcinoma are induced by the human endogenous retroviral Syncytin-1 and regulated by TGF-beta.
Q36903459Promoter hypermethylation of the tumor-suppressor genes ITIH5, DKK3, and RASSF1A as novel biomarkers for blood-based breast cancer screening
Q35608684Prospective evaluation of serum tissue inhibitor of metalloproteinase 1 and carbonic anhydrase IX in correlation to circulating tumor cells in patients with metastatic breast cancer
Q55508030Publisher Correction: Evidence that breast cancer risk at the 2q35 locus is mediated through IGFBP5 regulation.
Q90242034Publisher Correction: Shared heritability and functional enrichment across six solid cancers
Q43927056Quality assured health care in certified breast centers and improvement of the prognosis of breast cancer patients
Q43166541Quantification of fatty acid ethyl esters (FAEE) and ethyl glucuronide (EtG) in meconium from newborns for detection of alcohol abuse in a maternal health evaluation study
Q36009422RAD51B in Familial Breast Cancer
Q90547034RANKL and OPG and their influence on breast volume changes during pregnancy in healthy women
Q47999353Randomised, open-label, phase II study comparing the efficacy and the safety of cabazitaxel versus weekly paclitaxel given as neoadjuvant treatment in patients with operable triple-negative or luminal B/HER2-negative breast cancer (GENEVIEVE).
Q35576256Re-Challenging Taxanes in Recurrent Breast Cancer in Patients Treated with (Neo-)Adjuvant Taxane-Based Therapy
Q98158747Refined cut-off for TP53 immunohistochemistry improves prediction of TP53 mutation status in ovarian mucinous tumors: implications for outcome analyses
Q35155449Refined histopathological predictors of BRCA1 and BRCA2 mutation status: a large-scale analysis of breast cancer characteristics from the BCAC, CIMBA, and ENIGMA consortia
Q26830250Relevance of health economics in breast cancer treatment - the view of certified breast centres and their patients
Q42236299Reliability of an e-PRO Tool of EORTC QLQ-C30 for Measurement of Health-Related Quality of Life in Patients With Breast Cancer: Prospective Randomized Trial.
Q36799061Replication of Epigenetic Postpartum Depression Biomarkers and Variation with Hormone Levels
Q45951126Reproductive profiles and risk of breast cancer subtypes: a multi-center case-only study.
Q48070774Response to "screening depression during and after pregnancy using the EPDS".
Q34201814Risk Factors for Endometriosis in a German Case-Control Study
Q36771007Risk and risk assessment for breast cancer: molecular and clinical aspects
Q37300024Risk of estrogen receptor-positive and -negative breast cancer and single-nucleotide polymorphism 2q35-rs13387042.
Q37624504Risk of ovarian cancer and the NF-κB pathway: genetic association with IL1A and TNFSF10
Q54950358Risk, Prediction and Prevention of Hereditary Breast Cancer - Large-Scale Genomic Studies in Times of Big and Smart Data.
Q37453871Role of genetic polymorphisms and ovarian cancer susceptibility
Q36545934SNP-SNP interaction analysis of NF-κB signaling pathway on breast cancer survival
Q55013059Saliva samples as a source of DNA for high throughput genotyping: an acceptable and sufficient means in improvement of risk estimation throughout mammographic diagnostics.
Q64328965Self-reported Improvement in Side Effects and Quality of Life With Integrative Medicine in Breast Cancer Patients
Q36320573Semi-automated De-identification of German Content Sensitive Reports for Big Data Analytics
Q39102961Semi-automated delineation of breast cancer tumors and subsequent materialization using three-dimensional printing (rapid prototyping).
Q42599064Shared decision-making in metastatic breast cancer: discrepancy between the expected prolongation of life and treatment efficacy between patients and physicians, and influencing factors
Q36089391Shared genetics underlying epidemiological association between endometriosis and ovarian cancer
Q61118451Shared heritability and functional enrichment across six solid cancers
Q64004349Shared heritability and functional enrichment across six solid cancers
Q54547212Single nucleotide polymorphism D1853N of the ATM gene may alter the risk for breast cancer.
Q44470032Single nucleotide polymorphisms in the progesterone receptor gene and association with uterine leiomyoma tumor characteristics and disease risk
Q44192343Socioeconomic status and depression during and after pregnancy in the Franconian Maternal Health Evaluation Studies (FRAMES).
Q40386096Standardized evaluation of tumor-infiltrating lymphocytes in breast cancer: results of the ring studies of the international immuno-oncology biomarker working group
Q64273100Standards Used by a Clinical and Scientific Endometriosis Center for the Diagnosis and Therapy of Patients with Endometriosis
Q59335365Supportive Infusions in Integrative Breast and Gynecological Oncology – Report on Patientsʼ Satisfaction and Self-reported Effects and Side Effects
Q52807512Survival Analysis After Neoadjuvant Chemotherapy With Trastuzumab or Lapatinib in Patients With Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer in the GeparQuinto (G5) Study (GBG 44).
Q46903050Survival after adding capecitabine and trastuzumab to neoadjuvant anthracycline-taxane-based chemotherapy for primary breast cancer (GBG 40--GeparQuattro).
Q55071239Survival after neoadjuvant chemotherapy with or without bevacizumab or everolimus for HER2-negative primary breast cancer (GBG 44-GeparQuinto)†.
Q62583463TILGen: A Program to Investigate Immune Targets in Breast Cancer Patients - First Results on the Influence of Tumor-Infiltrating Lymphocytes
Q33566957TP53-based interaction analysis identifies cis-eQTL variants for TP53BP2, FBXO28, and FAM53A that associate with survival and treatment outcome in breast cancer
Q52841976Targeted Intraoperative Radiotherapy Tumour Bed Boost During Breast Conserving Surgery after Neoadjuvant Chemotherapy in HER2 Positive and Triple Negative Breast Cancer.
Q47321009Targeted Intraoperative Radiotherapy Tumour Bed Boost during Breast-Conserving Surgery after Neoadjuvant Chemotherapy - a Subgroup Analysis of Hormone Receptor-Positive HER2-Negative Breast Cancer
Q39178659Targeted intraoperative radiotherapy tumour bed boost during breast-conserving surgery after neoadjuvant chemotherapy
Q48769304The 5-HTTLPR polymorphism modulates the influence on environmental stressors on peripartum depression symptoms.
Q49817640The BRCA2 c.68-7T > A variant is not pathogenic: A model for clinical calibration of spliceogenicity.
Q91178389The FANCM:p.Arg658* truncating variant is associated with risk of triple-negative breast cancer
Q33769034The HER2 phenotype of circulating tumor cells in HER2-positive early breast cancer: A translational research project of a prospective randomized phase III trial
Q37210385The International Endometriosis Evaluation Program (IEEP Study) - A Systematic Study for Physicians, Researchers and Patients
Q39147158The PI3K Pathway: Background and Treatment Approaches
Q35781316The SNP rs6500843 in 16p13.3 is associated with survival specifically among chemotherapy-treated breast cancer patients
Q36917100The UGT1A6_19_GG genotype is a breast cancer risk factor
Q36137764The contributions of breast density and common genetic variation to breast cancer risk
Q51781776The era of centers: the influence of establishing specialized centers on patients' choice of hospital.
Q28389045The influence of obesity on survival in early, high-risk breast cancer: results from the randomized SUCCESS A trial
Q36357800The integrative epigenomic-transcriptomic landscape of ER positive breast cancer
Q57265642The postmenopausal hormone replacement therapy-related breast cancer risk is decreased in women carrying the CYP2C19*17 variant
Q64258248The prognostic relevance of urokinase-type plasminogen activator (uPA) in the blood of patients with metastatic breast cancer
Q35024008The role of KRAS rs61764370 in invasive epithelial ovarian cancer: implications for clinical testing
Q36142060The role of genetic breast cancer susceptibility variants as prognostic factors
Q21195217The ubiquitin-like molecule interferon-stimulated gene 15 (ISG15) is a potential prognostic marker in human breast cancer
Q61814603Therapy Landscape in Patients with Metastatic HER2-Positive Breast Cancer: Data from the PRAEGNANT Real-World Breast Cancer Registry
Q34129643Time and Resources Needed to Document Patients with Breast Cancer from Primary Diagnosis to Follow-up - Results of a Single-center Study
Q52887281Tissue remodeling and nonendometrium-like menstrual cycling are hallmarks of peritoneal endometriosis lesions.
Q36539580Touch Imprint Cytology and Stereotactically-Guided Core Needle Biopsy of Suspicious Breast Lesions: 15-Year Follow-up
Q33432594Toxicity Assessment of a Phase III Study Evaluating FEC-Doc and FEC-Doc Combined with Gemcitabine as an Adjuvant Treatment for High-Risk Early Breast Cancer: the SUCCESS-A Trial
Q89961489Transcriptome-wide association study of breast cancer risk by estrogen-receptor status
Q62022868Trastuzumab Emtansine for Residual Invasive HER2-Positive Breast Cancer
Q47663023Treatment landscape of advanced breast cancer patients with hormone receptor positive HER2 negative tumors - Data from the German PRAEGNANT breast cancer registry
Q44267362Treatment of endometrial carcinoma - evidence based criteria
Q58797082Triple-Negative Breast Cancer Risk Genes Identified by Multigene Hereditary Cancer Panel Testing
Q47322152Tumour-infiltrating lymphocytes and prognosis in different subtypes of breast cancer: a pooled analysis of 3771 patients treated with neoadjuvant therapy
Q43215450Two naturally occurring variants of the serotonin receptor gene HTR3C are associated with nausea in pregnancy
Q92994868Two truncating variants in FANCC and breast cancer risk
Q45991085Ultrasound elastography of pulmonary lesions - a feasibility study.
Q47110841Update Breast Cancer 2017 - Implementation of Novel Therapies
Q52632717Update Breast Cancer 2018 (Part 1) - Primary Breast Cancer and Biomarkers.
Q52632715Update Breast Cancer 2018 (Part 2) - Advanced Breast Cancer, Quality of Life and Prevention.
Q59335358Update Breast Cancer 2018 (Part 3) – Genomics, Individualized Medicine and Immune Therapies – in the Middle of a New Era: Prevention and Treatment Strategies for Early Breast Cancer
Q59335362Update Breast Cancer 2018 (Part 4) – Genomics, Individualized Medicine and Immune Therapies – in the Middle of a New Era: Treatment Strategies for Advanced Breast Cancer
Q64102998Update Breast Cancer 2019 Part 1 - Implementation of Study Results of Novel Study Designs in Clinical Practice in Patients with Early Breast Cancer
Q64102991Update Breast Cancer 2019 Part 2 – Implementation of Novel Diagnostics and Therapeutics in Advanced Breast Cancer Patients in Clinical Practice
Q64273108Update Breast Cancer 2019 Part 3 – Current Developments in Early Breast Cancer: Review and Critical Assessment by an International Expert Panel
Q39046820Updates on the role of receptor activator of nuclear factor κB/receptor activator of nuclear factor κB ligand/osteoprotegerin pathway in breast cancer risk and treatment
Q38884752Use of complementary and integrative medicine among German breast cancer patients: predictors and implications for patient care within the PRAEGNANT study network
Q56968394Using Probability for Pathological Complete Response (pCR) as a Decision Support Marker for Neoadjuvant Chemotherapy in HER2 Negative Breast Cancer Patients - a Survey Among Physicians
Q41570633Using automated texture features to determine the probability for masking of a tumor on mammography, but not ultrasound
Q56342454Variants in genes encoding small GTPases and association with epithelial ovarian cancer susceptibility
Q33847791Variation in NF-κB signaling pathways and survival in invasive epithelial ovarian cancer
Q48096559Whole blood microRNAs as potential biomarkers in post-operative early breast cancer patients
Q36917641Willingness of Patients with Breast Cancer in the Adjuvant and Metastatic Setting to Use Electronic Surveys (ePRO) Depends on Sociodemographic Factors, Health-related Quality of Life, Disease Status and Computer Skills
Q52850868Zoledronate for patients with invasive residual disease after anthracyclines-taxane-based chemotherapy for early breast cancer - The Phase III NeoAdjuvant Trial Add-oN (NaTaN) study (GBG 36/ABCSG 29).
Q53050911[Documentation Time and Effort and Associated Resources for Patients with Primary Breast Cancer from Diagnosis to End of Follow-Up - Results of a Multicentre Validation].
Q53077783[Future of mammography-based imaging].
Q50449749[Pre-, peri- and postpartal depression].
Q54384993[Sebaceous breast carcinoma: report of a rare histological special subtype].
Q58587476[TILGen study-immunological targets in patients with breast cancer : Influence of tumor-infiltrating lymphocytes]
Q122925830p53 and ovarian carcinoma survival: an Ovarian Tumor Tissue Analysis consortium study
Q37414133rs2735383, located at a microRNA binding site in the 3'UTR of NBS1, is not associated with breast cancer risk
Q56334023rs495139 in the TYMS-ENOSF1 Region and Risk of Ovarian Carcinoma of Mucinous Histology

Search more.